|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:acquired_by
|
gptkb:none
|
|
gptkbp:ceo
|
Dr. A. J. K. K. K. K.
|
|
gptkbp:clinical_trial
|
ongoing
Phase 1
Phase 2
Phase 3
published in peer-reviewed journals
|
|
gptkbp:collaborates_with
|
academic institutions
|
|
gptkbp:develops
|
immuno-oncology therapies
|
|
gptkbp:employees
|
over 100
|
|
gptkbp:focuses_on
|
oncology
|
|
gptkbp:founded
|
gptkb:2014
|
|
gptkbp:funding
|
multiple
|
|
gptkbp:headquarters
|
gptkb:New_York,_USA
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Checkmate Pharmaceuticals
|
|
gptkbp:instruction_set
|
various candidates
|
|
gptkbp:investment
|
over $100 million
various venture capital firms
|
|
gptkbp:mission
|
to improve patient outcomes
|
|
gptkbp:partnership
|
various biotech companies
|
|
gptkbp:products
|
gptkb:CM-24
gptkb:CM-8
gptkb:CM-9
|
|
gptkbp:regulatory_compliance
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:research_areas
|
gptkb:Oncology
bladder cancer
head and neck cancer
|
|
gptkbp:research_focus
|
checkpoint inhibitors
T-cell engagers
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:vision
|
to lead in immuno-oncology
|
|
gptkbp:website
|
www.checkmatepharma.com
|
|
gptkbp:bfsParent
|
gptkb:Regeneron_Pharmaceuticals
gptkb:Regeneron
|
|
gptkbp:bfsLayer
|
4
|